A leading COVID-19 vaccine will be produced in Canada this summer.
The federal government announced Tuesday Novavax (NASDAQ:NVAX) will produce its COVID-19 vaccine at a still under construction facility in Montreal. A government source speaking on background, revealed the company has signed a memorandum of understanding to use the National Research Council’s facility and could begin producing vaccines in late July.
The U.S. drug maker plans to produce its COVID-19 vaccine at the National Research Council’s Biologics Manufacturing Centre in Montréal once both the vaccine candidate and the facility receive Health Canada approvals. Ottawa had previously signed an agreement with Novavax to provide up to 76M doses of its COVID-19 vaccine. Novavax said that it will explore a range of partnership opportunities to expand vaccine production in Canada, including partnerships with Canadian contract manufacturers.
